Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (81-90 of 229) with videos related to

Pageof 23
Sort By:
Health Economics Review|May 15, 2021
Mendelian randomization: estimation of inpatient hospital costs attributable to obesityKatherine Dick, John E Schneider, Andrew Briggs, et al.
The Journal of Emergency Medicine|December 7, 2011
Mobile phone use for contacting emergency services in life-threatening circumstancesOlivia Wu, Andrew Briggs, Tom Kemp, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 11, 2004
Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004)Andrew Briggs, Martin Buxton, Mike Drummond, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 15, 2022
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation CohortsJohannes Pöhlmann, Klas Bergenheim, Juan-Jose Garcia Sanchez, et al.
Health and Quality of Life Outcomes|September 22, 2020
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature reviewJacie T Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, et al.
Oncology|November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case StudyAndrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritisEwen Cummins, Christian Asseburg, Yogesh Suresh Punekar, et al.
Respiratory Medicine|December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspectiveMaurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Pageof 23

Showing results (81-90 of 229) with videos related to

Sort By:
Pageof 23
Health Economics Review|May 15, 2021
Mendelian randomization: estimation of inpatient hospital costs attributable to obesityKatherine Dick, John E Schneider, Andrew Briggs, et al.
The Journal of Emergency Medicine|December 7, 2011
Mobile phone use for contacting emergency services in life-threatening circumstancesOlivia Wu, Andrew Briggs, Tom Kemp, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 11, 2004
Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004)Andrew Briggs, Martin Buxton, Mike Drummond, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 15, 2022
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation CohortsJohannes Pöhlmann, Klas Bergenheim, Juan-Jose Garcia Sanchez, et al.
Health and Quality of Life Outcomes|September 22, 2020
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature reviewJacie T Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, et al.
Oncology|November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case StudyAndrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritisEwen Cummins, Christian Asseburg, Yogesh Suresh Punekar, et al.
Respiratory Medicine|December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspectiveMaurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Pageof 23